Skip to main content

Regeneron (REGN) Receives a Hold from RBC Capital

Tipranks - Tipranks - Tue Mar 3, 6:28AM CST

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Regeneron, with a price target of $765.00.

Claim 70% Off TipRanks Premium

Abrahams covers the Healthcare sector, focusing on stocks such as Regeneron, Biogen, and Incyte. According to TipRanks, Abrahams has an average return of 8.0% and a 50.60% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Regeneron with a $873.14 average price target.

See today’s best-performing stocks on TipRanks >>

Based on Regeneron’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.88 billion and a net profit of $844.6 million. In comparison, last year the company earned a revenue of $3.79 billion and had a net profit of $917.7 million

Read More on REGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).